Human Microbiome Market: Prominent Players, Globally..!

Posted by MV Mukund on March 1st, 2024

Overview of This Study:

In order to estimate the present size of the human microbiome market, this study includes four primary actions. A thorough investigation was conducted using secondary research methods to gather data about the market, its parent market, and its peer markets. The following stage involved conducting primary research to confirm these conclusions, hypotheses, and sizing with industry experts throughout the value chain. A combination of top-down and bottom-up methods was used to assess the overall market size. Subsequently, methods for data triangulation and market breakdown were employed to estimate the market size of various segments.

Global Growth Driving Factors:

The market is predicted to rise at a rapid pace due to the growing demand for natural and holistic treatments as well as the booming need for individualized medication. Nonetheless, market expansion is anticipated to be somewhat constrained by our incomplete knowledge of microbial interactions.

Projected Surge in Revenue Generation:

With a predicted revenue of --content--.3 billion in 2023 and a projected compound annual growth rate (CAGR) of 36.1% from 2023 to 2029, the worldwide human microbiome market is expected to reach .7 billion.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Leading Players:


The market for human microbiome is highly consolidated, with key players strategizing to capture majority of the market. Prominent players in the market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc.  (US),  YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland).

Different Growth Strategies Adopted by Them:

These include product launches, contracts, partnerships, mergers and acquisitions, and new product development activities to further expand their presence in the human microbiome market.

Seres Therapeutics, Inc. (US)

The goal of Seres therapies is to create microbiome therapies to cure dysbiosis-related illnesses. The company has a robust pipeline of drugs in different stages of development, such as SER-287, which is being developed for the treatment of inflammatory bowel disease (IBD), and SER-109, which is intended to treat recurrent Clostridium difficile infection (CDI).

Seres Therapeutics' cutting-edge technological platform, which integrates bioinformatics, machine learning, and high-throughput DNA sequencing to find possible treatment candidates from the human microbiome, is another aspect that helps explain the company's dominance in the microbiome sector. With the help of this platform, the business may create tailored treatments meant to enhance patient outcomes and return the microbiome to its natural equilibrium.

Enterome (France)

Enterome's creative approach to creating microbiome-based medicines and diagnostics has made it a major participant in the human microbiome market. It is creating a series of diagnostic tests based on the microbiota. Microbial biomarkers are used in these tests to help diagnose and track a number of conditions, such as liver disorders, colon cancer, and inflammatory bowel disease.

To further enhance its R&D endeavors, Enterome has also formed a number of strategic alliances. For instance, the business and Takeda Pharmaceuticals have been working together since 2016 to develop microbiome-based medicines for the management of inflammatory bowel disease. The business and Nestlé Health Science collaborated in 2022 to create treatments and diagnostics based on the microbiome.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

4D pharma plc (UK)


Because of its creative approach to the development of microbiome-based treatments, 4D Pharma Plc is one of the major participants in the human microbiome market. Utilizing a proprietary platform technology known as MicroRx, the business is able to recognize, separate, and cultivate live bacteria from the gut microbiome. Through the process of identifying and isolating helpful bacteria with therapeutic properties, this approach allows the company to create accurate and focused medicines for particular ailments.

Furthermore, 4D Pharma is developing a robust portfolio of microbiome-based treatments at different phases of development, including Phase II and Phase III clinical trials to treat diseases like asthma, cancer, and irritable bowel syndrome. In addition, the company collaborates with major pharmaceutical companies such as MSD and AstraZeneca, which provides it with access to their expertise and resources.

Geographical Growth Dynamics:

Asia Pacific: The fastest-growing region in the human microbiome market.


The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes.

Like it? Share it!


MV Mukund

About the Author

MV Mukund
Joined: March 18th, 2020
Articles Posted: 77

More by this author